一株降血压功能乳酸菌在模拟胃肠环境中抗性的研究

目的研究具有降血压功能乳酸菌DM9057株对pH、胆汁盐、胃蛋白酶及胰蛋白酶的耐受性。方法以MRS为基础培养基,模拟胃肠环境。结果 DM9057在pH2~3、胆汁盐浓度0.1%~0.3%、胃蛋白酶0.592~1.482μg/mL和胰蛋白酶14.24~72.32 U/g的条件下,37℃培养4 h,活菌数均能达到107CFU/mL以上。结论乳酸菌DM9057能顺利通过胃肠道,达到促进健康的作用。     

乳酸菌DM9054、DM9057的安全性评价

目的实验评价的2株乳酸菌DM9054和DM9057均分离于泡菜,分别具有降胆固醇和降血压功能,由于其功能性强,性状优良,故本实验对其安全性进行评价,为应用于食品药品生产提供参考依据。方法通过急性毒性试验、耐药性、机体指标、有害代谢产物的评价试验以及其他安全性评价试验检测两实验菌株的安全性。结果在一次性分别使用DM9054和DM9057大剂量灌胃后,动物体征指标无异常;两菌株对部分抗生素具有抗性,但不携带可转移的耐药质粒;使用实验菌株后,机体指标MDA、GSH和SAA的变化基本正常;菌株代谢不产生胆盐羟化酶、硝基还原酶和氨基脱羧酶,但产生乳酸;无溶血作用,长期使用,不发生易位现象。结论乳酸菌DM9054和DM9057总体上是安全的。     

菌株DM8320安全评价及其发酵乳对大鼠肾结石形成的影响

目的 对具有降解草酸能力的菌株DM8320进行初步安全性评价并观察其发酵乳对肾结石模型大鼠的影响.方法 通过检测DM8320的质粒,细菌易位试验以及急性毒性试验对DM8320进行初步安全性评价.构建大鼠肾结石模型的同时灌胃目的菌株的牛奶发酵乳,实验第29天,收集24 h尿液并检测尿液中钙离子、草酸的含量.取大鼠左肾制作石蜡切片,观察各个实验组结石发生情况.结果 菌株DM8320中不含质粒,未发生细菌易位现象,不具有毒性.DM8320发酵乳可降低肾结石模型大鼠尿中的草酸和钙离子含量.观察各组大鼠肾脏石蜡切片,结石组中结石含量最多,低剂量组次之,高剂量组肾结石结晶含量较少.结论 菌株DM8320具有一定的安全性,其发酵乳对Wistar大鼠肾结石的形成具有一定的抑制作用.     

超滤得到的海蜇酶解产物的降血脂功能评价

目的:探讨超滤对于海蜇酶解产物降血脂功能的提高作用。方法:海蜇通过中性蛋白酶酶解后,将超滤过的酶解产物和未超滤的酶解产物分别按照高、中、低三个剂量组喂食高血脂症大鼠模型42d,测定各组血脂水平并进行对照分析。结论:未超滤组的高、中剂量组和超滤组高中低剂量组喂食42d后均观察到大鼠血清总胆固醇(TC)、甘油三酯(TG)的降低,其中未超滤中剂量组(灌胃剂量5 mg/kg.BW)血清总胆固醇(TC)值为2.45±0.28mmol/L,超滤低剂量组(灌胃剂量0.3mg/kg.BW)血清总胆固醇(TC)值为2.61±0.33mmol/L,均明显低于高脂模型对照组(3.38±0.22 mmol/L),未超滤低剂量组(灌胃剂量3mg/kg.BW)血清总胆固醇(TC)值为2.82±0.38mmol/L,相对于高脂模型对照组(3.38±0.22 mmol/L)无显著差异;未超滤中剂量组(灌胃剂量5 mg/kg.BW)甘油三酯(TG)值为0.90±0.21mmol/L,超滤低剂量组(灌胃剂量0.3mg/kg.BW)甘油三酯(TG)值为0.93±0.14 mmol/L,均明显低于高脂模型对照组(1.21±0.20 mmol/L),未超滤低剂量组(灌胃剂量3mg/kg.BW)甘油三酯(TG)值为1.18±0.12mmol/L,相对于高脂模型对照组(1.21±0.20 mmol/L)无显著差异。结论:海蜇多肽的酶解产物具有降血脂功能,超滤能够有效提高海蜇酶解产物的降血脂活性。     

降血尿酸乳酸菌筛选及其对高尿酸血症模型大鼠作用研究

目的 提出利用具特殊活性乳酸菌来预防、治疗高尿酸血症方法,筛选具有较高降血尿酸活性的乳酸菌.方法 基于RP-HPLC方法,通过检测培养液培养前后肌苷、鸟苷含量变化,筛选出具有最快核苷分解速率的乳酸菌株作为候选菌株.并将其施用于高尿酸血症模型大鼠,观察对模型大鼠血尿酸含量影响.结果 获得具有最佳核苷分解速率的菌株DM9218.动物实验结果表明DM9218干预组的血尿酸浓度(219.25±21.98) μmol/L明显低于模型组(311.75±27.07) μmol/L(P＜0.05).结论 菌株DM9218具有最快的核苷分解速率,对高尿酸血症大鼠具有明显的降血尿酸作用.菌株DM9218为植物乳杆菌(Lactobacillus plantarum).     

Val-Glu-Pro对原发性高血压大鼠的体内降压作用

Val-Glu-Pro(VEP)是从钝顶螺旋藻(Spirulina platensis)中发现的一种血管紧张素转化酶(ACE)抑制肽.以原发性高血压大鼠(SHR)为模型,检测单次口服和一周间口服VEP的降压效果,并通过Real-timePCR和酶联免疫吸附法(ELISA)探索其对肾素-血管紧张素系统(RAS)主要成分在SHR大鼠肾脏和血清中的表达调控作用.结果表明:口服VEP的最低有效降压剂量为5mg/kg,加大剂量后表现出剂量效应,最低加权收缩压(WSBP)出现在口服后6h,最低加权舒张压(WDBP)出现在口服后4 h.在一周间口服试验中,10 mg/kg VEP处理组的WSBP在第5日显著低于负对照组.此外,口服VEP显著下调了SHR大鼠肾脏中肾素(renin)、ACE、血管紧张素Ⅱ(AngⅡ)类型1受体(AT1)的mRNA表达,并上调AngⅡ类型2受体(AT2)的mRNA表达,说明VEP的降压效果可能与对RAS系统的抑制作用相关,在高血压的预防和治疗中具有潜在的应用前景.     

具有降胆固醇功能益生菌的筛选研究

目的通过体外实验从发酵制品及人体肠道内分离筛选出安全高效的降胆固醇乳酸菌,并研究其生理生化特性,为今后功能性乳制品的开发提供优良菌种。方法应用MRS．胆固醇培养基液体发酵法进行目的菌株筛选,并测定其耐酸及耐胆盐等能力。结果筛选出4株具有降胆固醇能力的乳酸菌,其降解率分别为DM8403163．1％、DM8403470．3％、DM850381．1％、DM8605663．1％;同时4株乳酸菌均表现出不同程度的耐酸及耐胆盐能力,其中DM86056能力最强,其他3株乳酸菌次之;经鉴定,DM84031为保加利亚乳杆菌、DM84034为嗜热链球菌、DM8503为詹氏乳杆菌、DN86056为屎肠球菌。结论经上述实验综合比较,DM86056降胆固醇能力比较强且耐酸及耐胆盐等能力也较强,因此有待于将其应用于动物体内进行深入研究。     

丁咯地尔和α- 硫辛酸对糖尿病大鼠肾功能的保护作用研究

目的:研究丁咯地尔和α-硫辛酸(ALA)对糖尿病(DM)大鼠肾功能的保护作用。方法:雄性SD大鼠用链脲佐菌素(60 mg/kg)腹腔注射诱导DM。大鼠随机分为健康组(NC)、DM组(DMC)、DM+ALA组(ALA组)、DM+丁咯地尔组(丁咯地尔组)。ALA组和丁咯地尔组每天给予ALA 100 mg/kg灌胃和丁咯地尔(0.1 g/kg)腹腔注射,NC组和DMC组大鼠给予等量生理盐水每日灌胃。干预4周后,测观察治疗后大鼠血糖、尿素氮、血肌苷,内生肌苷清除率、24小时尿蛋白排泄率,比色法检测血清抗氧化酶和丙二醛(MDA)含量。结果:①丁咯地尔和α-硫辛酸降低糖尿病大鼠的尿素氮、血肌苷、24h尿白蛋白排泄率、丙二醛,增加超氧化物歧化酶②两种药物联合用药具有协同作用。结论:丁咯地尔和ALA可能通过抑制机体氧化应激水平,减低早期DM大鼠肾脏损害。     

干酪乳杆菌LC2W菌体的抗高血压作用

为探索干酪乳杆菌LC2W抗高血压作用的活性成分,收集了采用MRS液体培养基培养的干酪乳杆菌LC2W菌体,洗涤后重悬到10%(w/w)无菌脱脂乳中,至终浓度为1010CFU/mL。将菌悬液分成两组,一组直接进行冷冻干燥(活菌组);另一组在100℃水浴10 min后再进行冷冻干燥(灭活组)。按2.0×109CFU/Kg的剂量(活菌组)或相当浓度的灭活菌体对鼠龄17~18周的自发性高血压大鼠单次或连续灌胃15日,每日一次,对照组给予同样体积的脱脂乳。采用尾环法测定大鼠的收缩压和心率。连续灌胃试验中,于灌胃后4 h测定大鼠的收缩压(Systolic blood Pressure,SBP)和心律(Heart rate,HR)。采用称重法测定大鼠第1 d和第15 d时的体重。结果表明,灌喂LC2W菌体可以显著降低SHR的收缩压,这种作用在灌胃后4 h最显著(P<0.01);在连续灌胃试验中,无论是活菌组还是灭活组在第1、4、8、11和15 d都有显著的抗高血压作用(P<0.01)。未观察到LC2W菌体对实验动物心律和体重有明显的影响。上述结果表明在干酪乳杆菌菌体中存在热稳定性、具有抗高血压作用的物质。     

乳酸菌的降血压作用研究进展

高血压是最常见的心血管疾病之一,它是冠心病、脑猝死、心及肾功能衰竭的最主要发病因素。抗血压药物治疗高血压具有一定的副作用。最近的研究表明在牛乳蛋白中蕴含着多种具有不同生物活性的肽序列。研究表明,发酵乳制品中含有抗高血压肽,具有ACE体外抑制能力。而长期以来乳酸菌一直被用于人类食品,是传统乳酸发酵食品的重要菌株,具有潜在的改善机体健康作用,在降血压方面与药物比较起来安全性高。     

纯化自体外周血CD34^＋细胞移植治疗肢体重度缺血的中期疗效

目的探讨纯化CD34^＋细胞移植治疗肢体重度缺血的中期疗效。方法自2009年5月至2011年12月录入30例肢体重度缺血患者,男性29例,女性1例,平均年龄43 ± 12岁（23 - 75岁）,均不具备外科血管重建条件,共治疗31条下肢和4条上肢。G-CSF（5-10μg/kg）动员,第5天采集外周血单个核细胞,分选获得纯化CD34^＋细胞,肢体肌肉局部注射。根据移植细胞数分为3组：低剂量组（105/kg）、中剂量组（5 × 105/kg）和高剂量组（106/kg）。结果随访16 - 48个月,1个月和2个月时Wong-Baker FACES疼痛评分由术前7 ± 2降到3 ± 3（P〈 0.001）和1 ± 2（P〈 0.001）。术后3个月和6个月：最长无痛步行时间由术前的（5 ± 3）min分别延长至（12 ± 6）min（P〈 0.001）和（19 ± 5）min（P〈 0.001）;踝肱指数由术前的0.44 ± 0.20提高至0.62 ± 0.18（P= 0.04）和0.66 ± 0.14（P〈 0.001）;经皮氧分压由术前（26 ± 11）mmHg分别上升至（42 ± 11）mmHg（P 〈 0.001）和（56 ± 12）mmHg（P〈 0.001）。16例溃疡患者愈合11例。Kaplan Meier生存分析法计算16个月保肢率为84﹪（95﹪可信区间为0.63 - 0.94）。3个不同剂量组之间的比较,治疗效果差异无统计学意义,除了1个月时WFPRSC检测结果显示：高剂量组明显优于低、中剂量组。结论纯化自体外周血CD34^＋细胞移植治疗肢体重度缺血性疾病安全、可行,能够较为持久地缓解缺血,挽救肢体,改善患者生活质量。     

The antihypertensive activity of angiotensin-converting enzyme inhibitory peptide containing in bovine lactoferrin

Angiotensin I-converting enzyme (ACE) inhibitory peptide was isolated from the bovine lactoferrin hydrolysate using peptic hydrolysis by 2-step of reverse-phase high-performance liquid chromatography. This peptide was identified as Leu-Arg-Pro-Val-Ala-Ala and it produced a concentration-dependent inhibition of ACE activity in vitro with an IC50 value of about 4.14 microM. Also, this inhibition was identified as noncompetitive from the Lineweaver-Burk plot. Moreover, the antihypertensive activity of Leu-Arg-Pro-Val-Ala-Ala was investigated by the intravenous injection into spontaneously hypertensive rats (SHRs). A dose-dependent reduction of systolic blood pressure by this peptide was observed at 60 min after injection and it maximally decreased the blood pressure at a rate of 1 nmol/ml/kg. The blood pressure lowering activity of this peptide was calculated as 210% of captopril (10 pmol/ml/kg) that was used as positive control. Otherwise, identification of this peptide in the blood of SHRs was carried out chromatographically. Reduction of blood pressure coincides with the peak peptide concentration in the serum. Thus, we conclude that this peptide inhibits ACE activity in vitro and lowers systolic blood pressure in spontaneously hypertensive rat.     

Antihypertensive effect of angiotensin I-converting enzyme inhibitory peptides from a sesame protein hydrolysate in spontaneously hypertensive rats

Sesame peptide powder (SPP) exhibited angiotensin I-converting enzyme (ACE) inhibitory activity, and significantly and temporarily decreased the systolic blood pressure (SBP) in spontaneously hypertensive rats (SHRs) by a single administration (1 and 10 mg/kg). Six peptide ACE inhibitors were isolated and identified from SPP. The representative peptides, Leu-Val-Tyr, Leu-Gln-Pro and Leu-Lys-Tyr, could competitively inhibit ACE activity at respective Ki values of 0.92 microM, 0.50 microM, and 0.48 microM. A reconstituted sesame peptide mixture of Leu-Ser-Ala, Leu-Gln-Pro, Leu-Lys-Tyr, Ile-Val-Tyr, Val-Ile-Tyr, Leu-Val-Tyr, and Met-Leu-Pro-Ala-Tyr according to their content ratio in SPP showed a strong antihypertensive effect on SHR at doses of 3.63 and 36.3 microg/kg, which accounted for more than 70% of the corresponding dosage for the SPP-induced hypotensive effect. Repeated oral administration of SPP also lowered both SBP and the aortic ACE activity in SHR. These results demonstrate that SPP would be a beneficial ingredient for preventing and providing therapy against hypertension and its related diseases.     

The antihypertensive effect of U-0521 (3′,4′-dihydroxy-2-methylpropiophenone)

The synthetic catechol, U-0521, (3′,4′-dihydroxy-2-methylpropiophenone) is a competitive inhibitor of both tyrosine hydroxylase and catechol-O-methyltransferase. Continuous subcutaneous administration of 10 μmoles per day of U-0521 via Alzet osmotic minipumps to adult male Spontaneously Hypertensive Rats (SHR) reduced blood pressure from 160 mmHg to 125 mmHg. This effect occurred within two days, persisted for the two weeks that the pumps were in place, and reversed gradually upon cessation of U-0521 administration. Similar treatment of U-0521 to normotensive Wistar Kyoto rats (WKY) did not result in a similar hypotentensive effect. Subcutaneous administration of the same dose to juvenile SHRs led to a blockade in the expression of hypertension. After the five week treatment period, the blood pressure of the U-0521 treated animals escalated rapidly to match the saline treated controls. The antihypertensive effect of U-0521 on SHRs also occured when the compound was delivered by the oral route at the rate of 50 mg/kg/day.     

内毒素在大剂量顺铂所致大鼠急性肾损伤过程中的变化及意义

目的利用大剂量顺铂（cisplatin,DDP）所致大鼠急性肾功能衰竭的动物模型,观察外周血内毒素（endotoxin）在大鼠急性肾损伤中的变化及其意义。方法SD大鼠36只,雌雄各半,依体重随机分为DDP用药6h、48h、对照组和生理盐水（NS）用药6h、48h、对照组,每组6只。10mg／kgDDP单次腹腔内注射,等量Ns对照。观察并记录用药后对照组大鼠的毒副反应;用药6、48h各组大鼠无菌条件下心脏穿刺取血、肝素抗凝,检测外周血内毒素含量,同时内眦静脉取血,测定血清尿素氮、肌酐浓度,并进行统计学分析。结果DDP用药后6h,大鼠体重开始明显降低,用药48h后,大鼠腹泻逐渐加重,用药3d后大鼠死亡。DDP用药后6h大鼠血尿素氮、肌酐的含量与对照组比较差异无显著性（P〉0．05）;DDP用药后48h血尿素氮升至（18．71±9．9）mmol／L,明显高于对照组（7．48±0．6）mmol／L（P〈0．05）,同时血肌酐含量亦升至（49．6±14．1）μmol／L,与对照组（27．17±1．7）μmol／L比较差异具有显著性（P〈0．05）。DDP用药后6h所有大鼠外周血内毒素含量都低于0．0218Eu／rrd最低检出限,明显低于NS对照组大鼠（0．3141±0．1477）Eu／ml（P〈0．01）;DDP用药后48h大鼠外周血内毒素的含量增高均超过0．70Eu／ml最高检出限,明显高于NS对照组大鼠（0．1661±0．1198）Eu／ml（P〈0．01）。结论外周血内毒素含量的变化与大剂量顺铂所致大鼠急性肾损伤早期的发病机制无关,但与大鼠肾功能衰竭有关的发生相关。     

1461名老年患者血压波动与颈动脉斑块形成关系的研究

目的：除了血压水平的高低以外,血压波动也是造成人体靶器官损伤的独立危险因素。本研究以老年男性人群为研究对象,观察血压波动（BPV）与颈动脉斑块形成的关联性。方法：本研究选用1461名患有动脉硬化的老年男性患者为研究对象,将入选对象分为：非颈动脉斑块组和颈动脉斑块组,根据24小时动态血压测定（ABPM）中收缩压（SBP）、舒张N（DBP）的数据,用”个体血压波动法”测定每个患者的血压波动,分析探讨血压波动与颈动脉斑块形成之间的关联性。结果：①颈动脉斑块的形成与24小时收缩期血压波动（SBPV）密切相关（8-3±2．1mmHgVS7．9士2．0mmHg;P〈0．001）,其中与白昼（6：00．22：00）SBPV有关（8．1±2．1mmHgVS7．7土2．1mmHg：P〈0．001）,而与夜间（22：00-6：00）SBPV关系不明显（8,9±3．8mmHgVS8,6±3．7mmHg;P〉0．05）。②与24小时舒张期血压波动（DBPV）有关（5．6±1．4mmHgVS5．4±1．4mmHg;P〈0．05）,其中与白昼（6：00．22：00）舒张期血压波动有关（5．4±1．4mmHgVS5．2士1．4mmHg;P〈0．05）,而与夜间舒张期血压波动无关（6．2±2．7mmHgVS5．9±2．5mmHg;P〉0．05）。结论：在老年男性人群中,颈动脉斑块的形成与收缩期和舒张期血压波动均有关系,主要表现在白昼血压波动。     

Antihypertensive Effect of Angiotensin I-Converting Enzyme Inhibitory Peptides from a Sesame Protein Hydrolysate in Spontaneously Hypertensive Rats

Sesame peptide powder (SPP) exhibited angiotensin I-converting enzyme (ACE) inhibitory activity, and significantly and temporarily decreased the systolic blood pressure (SBP) in spontaneously hypertensive rats (SHRs) by a single administration (1 and 10 mg/kg). Six peptide ACE inhibitors were isolated and identified from SPP. The representative peptides, Leu-Val-Tyr, Leu-Gln-Pro and Leu-Lys-Tyr, could competitively inhibit ACE activity at respective Ki values of 0.92 μM, 0.50 μM, and 0.48 μM. A reconstituted sesame peptide mixture of Leu-Ser-Ala, Leu-Gln-Pro, Leu-Lys-Tyr, Ile-Val-Tyr, Val-Ile-Tyr, Leu-Val-Tyr, and Met-Leu-Pro-Ala-Tyr according to their content ratio in SPP showed a strong antihypertensive effect on SHR at doses of 3.63 and 36.3 μg/kg, which accounted for more than 70% of the corresponding dosage for the SPP-induced hypotensive effect. Repeated oral administration of SPP also lowered both SBP and the aortic ACE activity in SHR. These results demonstrate that SPP would be a beneficial ingredient for preventing and providing therapy against hypertension and its related diseases.     

Anti-hypertensive activity of genetically modified soybean seeds accumulating novokinin

Novokinin (Arg-Pro-Leu-Lys-Pro-Trp), which has been designed based on the structure of ovokinin (2-7), significantly reduces the systolic blood pressure at a dose of 100 microg/kg after oral administration in spontaneously hypertensive rats (SHRs). In this study, we generated a transgenic soybean which accumulates novokinin. A vector encoding a modified beta-conglycinin alpha' subunit (4novokinin-alpha') in which four novokinin sequences have been incorporated by site-directed mutagenesis was introduced into somatic embryos by whisker-mediated gene transformation to produce a transgenic soybean. The 4novokinin-alpha' occupied 0.5% of total soluble protein and 5% of the beta-conglycinin alpha' subunit in the transgenic soybean seeds. Protein extracted from the transgenic soybean reduced systolic blood pressure after single oral administration in SHRs at a dose of 0.15 g/kg. Defatted flour from the transgenic soybean also reduced the systolic blood pressure at a dose of 0.25 g/kg. Thus, the 4novokinin-alpha' produced in soybean exhibited an anti-hypertensive activity in SHRs after oral administration.     

ACE activity during the hypotension produced by standardized aqueous extract of Cecropia glaziovii Sneth: A comparative study to captopril effects in rats

To evaluate the effect of the standardized aqueous extract (AE) of Cecropia glaziovii Sneth on the plasma angiotensin I converting enzyme (ACE-EC 3.4.15.1) activity, rats were treated with a single dose of AE (1 g/kg, p.o.) or repeatedly (0.5 g/kg/bid, p.o.) for 60 days. Captopril (50 mg/kg, p.o.) was used as positive control on the same animals. The effects on the blood pressure were recorded directly from the femoral artery (single dose), or indirectly by the tail cuff method (repeated doses) in conscious rats. The plasma ACE activity was determined spectrofluorimetrically using Hypuril-Hystidine-Leucine as substrate. The arterial blood pressure, heart rate and plasma ACE activity were not significantly modified within 24 h after a single dose administration of AE. Comparatively, blood pressure in captopril treated rats was reduced by 7-16% and heart rate was increased by 10-20% from 30 min to 24 h after drug administration. ACE activity after captopril presented a dual response: an immediate inhibition peaking at 30 min and a slow reversal to 32% up-regulation after 24 h. To correlate the drug effects upon repeated administration of either compound, normotensive rats were separated in three groups: animals with high ACE (48.8+/-2.6 nmol/min/ml), intermediate ACE (39.4+/-1.4 nmol/min/ml) and low ACE (23.5+/-0.6 nmol/min/ml) activity, significantly different among them. Repeated treatment with AE reduced the mean systolic blood pressure (121.7+/-0.5 mm Hg) by 20 mm Hg after 14 days. The hypotension was reversed upon washout 60 days afterwards. Likely, repeated captopril administration decreased blood pressure by 20 mm Hg throughout treatment in all groups. After 30 days treatment with AE (0.5 g/kg/bid, p.o.) the plasma ACE activity was unchanged in any experimental group. After captopril (50 mg/kg/bid, p.o.) administration the plasma ACE activity was inhibited by 50% within 1 h treatment but it was up-regulated by 120% after 12 h in all groups. It is concluded that the hypotension produced by prolonged treatment with AE of C. glaziovii is unrelated to ACE inhibition.     

右心导管法测大鼠肺动脉压力的改良

目的:目前常用的测量大鼠肺动脉压力的右心导管法存在一定的缺陷,且很难得到典型的压力曲线图。本实验对大鼠经颈外静脉插管与测压的方法进行改良,同时与已有报道的实验结果进行比较,并提供正常SD大鼠右心房、右心室及肺动脉的压力参考值及典型的压力曲线图,以协助研究人员判断导管位置,及时调整导管的深度和方向,快速测出肺动脉压力。方法:雌雄不分的清洁级SD大鼠共30只,体重180~230 g,6~7周龄。应用自制的末端呈一弧形的PE-10管,采用改良后的右心导管法,经颈外静脉插入大鼠心腔及肺动脉,检测并计算大鼠右心房、右心室和肺动脉的收缩压、舒张压及肺动脉平均压。结果:右心房压力波动较平缓,呈小波浪形;右心室压力曲线波动大,骤升骤降;肺动脉压力曲线有重搏波。正常SD大鼠右心房舒张压为(2.03±2.56)mmHg,收缩压为(2.82±1.85)mmHg;右心室舒张压为(5.72±3.99)mmHg,收缩压为(18.73±4.80)mmHg;肺动脉舒张压为(15.27±2.64)mmHg,收缩压为(18.49±2.53)mmHg,肺动脉平均压为(16.34±2.32)mmHg。右心室收缩压与肺动脉收缩压无明显差异(P0.05)。结论:改良后的方法可准确到达大鼠肺动脉,提供的压力参考值及曲线图有助于研究人员顺利完成测压实验。